Renal gelsolin amyloidosis as a rare cause of proteinuria: a case report and literature review Authors: Miner Wang, Jianxiang Chen, Tingyuan Chu, Henglan Wu Published: 2025 ABSTRACT AbstractBackgroundHereditary gelsolin amyloidosis (AGel amyloidosis) is a rare autosomal dominant systemic amyloidosis caused by mutations in the Gelsolin (GSN) gene encoding gelsolin. The condition is characterized by a triad of cranial nerve involvement, corneal lattice amyloidosis, and skin laxity, with a small proportion of cases involving the kidneys and heart. We report the first case of renal AGel amyloidosis associated with a c.487G > A mutation in the GSN gene, presenting as isolated proteinuria.Case presentationA 55-year-old woman presented with proteinuria. She had a history of hypertension and diabetes but no family history of kidney disease. Physical examination revealed no abnormalities in the heart, eyes, nerves, or skin. Urinalysis showed moderate proteinuria (1975.5 mg/24h), and serum creatinine was normal (0.71 mg/dL). Renal biopsy revealed Congo red-positive glomeruli on light microscopy, with apple-green birefringence under polarized light. Electron microscopy showed randomly arranged fibrillar deposits in the glomeruli. Mass spectrometry analysis confirmed that the deposits were consistent with gelsolin protein. Genetic testing revealed a heterozygous missense mutation in the GSN gene (NM_198252.3; c.487G > A; p.Asp163Asn). The patient was diagnosed with AGel amyloidosis. Additionally, we compiled the phenotypic and genotypic characteristics of previously reported AGel amyloidosis cases.ConclusionWe report a novel mutation in AGel amyloidosis with renal involvement. This case highlights the importance of renal biopsy, mass spectrometry analysis, and genetic testing in establishing a definitive diagnosis. It expands the known spectrum of GSN gene mutations and further supports the heterogeneity of the AGel amyloidosis phenotype.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12882-025-04599-x.Keywords: Gelsolin, Hereditary gelsolin amyloidosis, FAF, Kidney amyloidosis, Proteinuria Background Hereditary gelsolin amyloidosis (AGel amyloidosis), also known as Meretoja syndrome or Finnish-type familial amyloidosis (FAF), is a rare autosomal-dominant systemic amyloidosis. It is one of the most common genetic disorders in Finland, with 100% penetrance. The condition is caused by mutations in the Gelsolin gene (GSN) located on chromosome 9 [1]. Gelsolin is a cytoplasmic calcium-sensitive protein that contains six gelsolin-like domains (designated G1 to G6) and eight calcium-binding sites. It plays a crucial role in regulating actin dynamics required for cell movement and morphological changes [2]. In humans, gelsolin exists in both an intracellular form (81 kDa) and an extracellular secretory form (plasma gelsolin, 83 kDa), with the latter produced through alternative splicing of the former [3]. To date, at least 15 pathogenic mutations in the GSN gene have been reported. Although there is no accurate data on the prevalence of different mutation types, the most common mutation is c.654G >A, a guanine (G) to adenine (A) substitution at position 654 of the GSN coding region (q32-34) on chromosome 9, resulting in an aspartic acid (Asp) to asparagine (Asn) change at position 214 [4]. This mutation disrupts the G2 calcium-binding site, leading to instability in the overall domain structure [5]. The misfolded and partially folded forms are susceptible to cleavage by trans-Golgi network proteases [6], generating 5 kDa and 8 kDa protein fragments that aggregate into amyloid fibrils, which subsequently deposit in various tissues [7], ultimately resulting in a variety of clinical manifestations. The disease was first described by the Finnish ophthalmologist Jouko Meretoja in 1969 [8]. Clinically, it is characterized by a classic triad of corneal lattice amyloidosis, cranial and peripheral neuropathy, and cutis laxa [9]. While uncommon, renal involvement has been reported in some patients. Among 1,109 renal amyloid samples evaluated at the Mayo Clinic Nephrology Pathology Laboratory between 2005 and 2015, only 12 cases (1.17%) were identified as AGel amyloidosis [10]. Here, we report an unusual case presenting with isolated proteinuria and a c.487G > A mutation in the GSN gene. Case presentation A 50-year-old Chinese woman was admitted to the hospital due to proteinuria discovered one day prior to admission. Her medical history included hypertension and type 2 diabetes mellitus. She had no cardiac, ophthalmic, neurologic, or skin abnormalities on physical exam. Urinalysis revealed moderate proteinuria of 1957.5 mg/24h, and urinary microalbumin concentration of 1319.9 mg/L. During her hospitalization, laboratory findings showed her serum albumin was 37.1 g/L, serum creatinine was 0.71 mg/dL (eGFR 113 mL/min/1.73m2 by CKD-EPI equation). Serum immunoglobulins and urine free light chains were normal. Serum and urine immunofixation electrophoresis were negative for monoclonal immunoglobulins. A kidney biopsy was performed to investigate the cause of proteinuria. There were 26 glomeruli present, of which 9 were globally sclerosed. Congo red staining was positive in the glomeruli, with apple-green birefringence under polarized light (Fig. 1a). Periodic acid–Schiff (PAS) staining demonstrated moderate to marked mesangial expansion with deposition of homogeneous, pale, amorphous material, without evident mesangial cell proliferation (Fig. 1b). No crescent formation was observed. Periodic acid–silver methenamine (PASM) staining showed no distinct eyelash-like structures along the outer aspect of the glomerular basement membrane (Fig. 1c). Masson’s trichrome staining revealed no definite fuchsinophilic deposits within glomeruli (Fig. 1d). The renal tubules exhibited protein casts, multifocal atrophy (approximately 30% of the cortical area), multifocal inflammatory cell infiltration, and moderate interstitial fibrosis. Small interlobular arteries demonstrated intimal thickening, elastic lamina splitting, and luminal narrowing, with several arterioles showing hyaline degeneration. Immunofluorescence revealed albumin reabsorption droplets in tubular epithelial cells (Fig. 1e-f). Pathological images of renal tissue. (a) Congo red staining shows amyloid deposits in the glomeruli with apple-green birefringence under polarized light (Congo red + polarized light, ×400). (b) Periodic acid–Schiff (PAS) staining shows moderate mesangial expansion with deposition of homogeneous, pale, amorphous material (PAS, ×400). (c) Periodic acid-silver methenamine (PASM) staining shows no distinct “hairy” structures along the outer aspect of the glomerular basement membrane (PASM, ×400). (d) Masson’s trichrome staining does not reveal obvious red-staining (acidophilic) amyloid deposits within glomerular compartments (Masson, ×400). (e) Negative staining for kappa light chains. (f) Negative staining for lambda light chains. (g) Segmental, mild thickening of the glomerular basement membrane. Mesangial matrix expansion with extensive foot-process effacement involving approximately 60-70% of podocytes (EM, ×6,000). (h) Electron-dense, fibrillar material is presented in the mesangial area and subendothelial regions of the glomerular capillary loops, with characteristic “spiculated” subendothelial changes. High-power views show randomly arranged, non-branching fibrils measuring approximately 8-12 nm in diameter (EM, ×40,000).b(a) Electron microscopy demonstrated mild, segmental thickening of the glomerular basement membrane (GBM), mesangial expansion with widespread podocyte foot-process effacement (approximately 60-70%), and low-electron-density deposits within the mesangial area and subendothelial region of the GBM. The subendothelial deposits exhibited a fibrillar, “spicule-like” appearance, consisting of randomly arranged, non-branching fibrils measuring approximately 8-12 nm in diameter under high magnification. No deposits were detected in the renal interstitium or vessel walls (Fig. 1g-h). A preliminary diagnosis of renal amyloidosis of uncertain type, coexisting with diabetic nephropathy, was established. This diagnosis was supported by Congo red positivity with apple-green birefringence under polarized light; electron microscopy showing randomly oriented fibrils measuring 8-12 nm in diameter; and negative immunofluorescence for immunoglobulins (including κ and λ light chains), thereby excluding fibrillary glomerulonephritis. The presence of glomerulosclerosis, interstitial fibrosis and tubular atrophy (IFTA), and interstitial inflammation was consistent with diabetic nephropathy. Clinically, the patient presented with moderate proteinuria that was likely multifactorial, resulting from both diabetic nephropathy and renal amyloidosis. To further clarify the protein composition of the deposits, mass spectrometry (MS) was performed (Fig. 2a). The results showed a significant number of spectra matching serum amyloid P component (SAP), apolipoprotein E (ApoE), and gelsolin, indicating a diagnosis of AGel amyloidosis (Fig. 2a). Peripheral blood samples were collected to screen for GSN gene mutations in the proband. Sequencing results revealed a previously unreported sequence variation, a guanine (G) to adenine (A) substitution at nucleotide 487 of the coding sequence, corresponding to an aspartic acid (Asp) to asparagine (Asn) change at amino acid position 163 (Fig. 2b). The patient’s parents are deceased, and there were no clinical symptoms in her brother. Her 33-year-old son has a history of ureteral stones, but urinalysis showed no proteinuria. Genetic testing has not been performed for her brother or son (Fig. 3). At the request of the patient and her family members, the patient’s brother and son did not undergo genetic testing. Mass spectrometry analysis and GSN gene sequencing. (a) Mass spectrometry analysis. The x-axis represents the identified protein types, and the y-axis represents the number of spectra. Mass spectrometry identified higher abundances of amyloid-associated proteins SAP and ApoE, suggesting amyloid deposition. Among the known profiling proteins, gelsolin (Gel) showed the highest relative abundance, consistent with AGel amyloidosis. (b) GSN gene sequencing. The red arrow indicates the mutation site: guanine (G) is substituted by adenine (A) at nucleotide 487 of the coding sequence, resulting in a missense change (aspartic acid [Asp] to asparagine [Asn] at codon 163) Pedigree of the family. Male members are represented by squares; female members by circles; deceased members are indicated by a slash; affected members are represented by filled symbols; members who provided DNA are marked with a “+” symbol; the proband is indicated by an arrow (II-2) Based on the comprehensive evaluation of the patient’s clinical presentation, laboratory findings, renal biopsy pathology, mass spectrometry analysis, and genetic testing results, a final diagnosis of AGel-related renal amyloidosis (Finnish-type amyloidosis) was established. The patient was prescribed a multi-drug regimen including nifedipine extended-release (30 mg twice daily) and sacubitril/valsartan (100 mg twice daily) for blood pressure management, metformin (0.25 g three times daily) for blood glucose management, dapagliflozin (10 mg once daily) for reduction of proteinuria, and atorvastatin calcium (20 mg once daily) for lipid-lowering therapy. Following the initiation of this treatment regimen, the patient exhibited well-controlled blood pressure and blood glucose levels, alongside reduced urinary microalbumin concentration. The patient was seen after 1 year, laboratory findings showed urinary microalbumin concentration of 308 mg/L, serum creatinine of 0.96 mg/dL (eGFR 80 mL/min/1.73m2 by CKD-EPI equation) and serum albumin of 42.6 g/L. Discussion and conclusion While AGel amyloidosis has a higher prevalence in Finland, cases have been reported globally. Finland established The Finnish National Gelsolin Amyloidosis Registry (FIN-GAR) in 2013 [11], and the estimated number of patients in Finland ranges from 600 to 1,000 [12, 13]. Through a literature review, we compiled the phenotypic and genotypic characteristics of AGel amyloidosis (Supplementary Material Table S1), which suggests that variations at different loci of the GSN gene contribute to phenotypic differences. The patients included in this review (n = 164) were compared with those in the Finnish FIN-GAR Phase II study (n = 261) to understand the phenotypic differences between patients from endemic and non-endemic areas. Compared with the FIN-GAR Phase II study, patients in the present cohort were diagnosed at an older age, less frequently exhibited features of the classical clinical triad, and showed a higher prevalence of proteinuria, which may reflect phenotypic differences associated with distinct genotypes (Table 1). Table 1Comparison of clinical characteristics between the FIN-GAR II study and present reviewCharacteristicFIN-GAR Phase II study (n = 261)Present review (n = 164)Gender distribution183 (70%) female, 78 (30%) male70 (42.7%) male, 90 (54.9%) femaleMean age of the patients (year)62.7 (range 26.3-85.8)59.8 (range 12–89)Median age of the patients (year)64.7 (interquartile range 54.9-71.2)60.0 (interquartile range 50.0-72.0)Mean age at diagnosis of AGel amyloidosis (year)40.7 (range 10.4-68.7)59.7 (range 10.0-89.0)Genetic testing (%)138 (52.9)152 (92.7)Clinical signs and symptomsCorneal lattice amyloidosis (%)231(88.5)119(72.6)Cataract (%)123(47.1)17(10.4)Drooping eye lids (%)225(86.2)53(32.3)Cutis laxa (%)219(83.9)89(54.3)Facial motor dysfunction (%)176(67.4)109(66.5)Proteinuria (%)35(13.1)35(21.3)Renal failure (%)14(5.4)4(2.4)Arrhythmia (%)20(n = 129, 15.5)22(13.4) Comparison of clinical characteristics between the FIN-GAR II study and present review Ocular symptoms of AGel amyloidosis typically manifest around the age of 30 and are characterized by corneal lattice amyloidosis caused by the deposition of gelsolin amyloid fibrils [14]. The hallmark feature is the accumulation of lattice lines in the anterior and middle stroma, visible under slit-lamp microscopy [15]. Corneal amyloidosis can be detected with Congo red staining, which imparts a characteristic apple-green birefringence to amyloid fibrils under polarized light. Histopathological examination with Congo red reveals amyloid deposits in the cornea (particularly in the anterior and middle stroma), conjunctiva, sclera, and the nerves and blood vessels of the eye [16]. Patients frequently experience corneal erosions due to reduced corneal sensitivity. Dry eye syndrome is a common condition exacerbated by a compromised blink reflex (mediated by the trigeminal nerve), reduced contraction of the orbicularis oculi muscle (facial nerve), and an increased evaporative surface area from ectropion, resulting from peripheral facial palsy. A rare instance of pigmentary retinopathy was reported in an Iranian family with AGel amyloidosis, a manifestation not observed in other cases [17]. Cranial nerve involvement is a primary neurological manifestation of AGel amyloidosis. Patients typically present with peripheral facial palsy in areas innervated by the upper division of the facial nerve, which slowly progresses to involve the lower division. Meretoja et al. reported that 137 (89%) patients aged > 40 years had partial or complete palsy of the upper division of the facial nerve. Other cranial nerves, including the trigeminal, glossopharyngeal, and hypoglossal nerves, are also frequently affected, leading to sensory loss, tongue atrophy, fasciculations, dysarthria, and sialorrhea [9]. Sensory peripheral neuropathy typically develops after the fourth or fifth decade of life, typically beginning in the lower limbs, although it rarely causes sensory ataxia in elderly patients [18]. Autonomic nerve involvement may present as orthostatic hypotension and cardiac conduction abnormalities [19, 20], and some patients may require the implantation of a pacemaker. The deposition of gelsolin amyloid fibrils in the dermal–epidermal junction (basement membrane zone) leads to various skin abnormalities, including skin laxity, thickening, and reduced elasticity. The characteristic facial feature is a mask-like facies [21]. Deposits within the sweat glands and hair follicles may result in alopecia, petechiae, and dry/itchy skin. Skin laxity significantly alters the patient’s facial appearance, limits facial expressions, restricts the field of vision, impairs speech, and affects other oral functions, severely impacting daily life. A study by Kiuru-Enari et al. involving 10 patients found that all exhibited characteristic skin laxity, clinically presenting as loose, sagging skin with reduced elasticity [12]. In the later stages of the disease, amyloid deposits in the glomeruli can result in clinical manifestations such as proteinuria and edema. Renal involvement is less common and generally mild in heterozygous patients. A study conducted at the Mayo Clinic Nephrology Pathology Laboratory from 2005 to 2015, which evaluated 1,109 renal amyloid samples, identified only 12 cases (1.17%) of AGel-related renal amyloidosis [10]. However, reports suggest that homozygous patients may develop severe nephrotic syndrome early in the disease course, which can eventually progress to ESRD, requiring dialysis or kidney transplantation [17, 22]. Renal biopsy in AGel amyloidosis patients typically reveals Congo red-positive eosinophilic deposits. Under light microscopy, mesangial and capillary wall expansion are typically observed, with Congo red-positive areas primarily confined to the glomeruli and rarely extending into the renal interstitium or vessel walls. Electron microscopy reveals amyloid fibrils arranged in parallel bundles or sheet-like formations in some areas. Furthermore, mass spectrometry can detectmutant peptides (gelsolin, apolipoprotein A-IV, and serum amyloid P component), making it useful for diagnosing different types of amyloidosis [23]. A cohort study involving 51 AGel amyloidosis patients found conduction disturbances in 22 (43%) patients; and after three years of follow-up, only 1 patient received pacemaker implantation, while another patient passed away [24]. Severe clinical cardiac manifestations are rare, with only one reported case of a patient with AGel amyloidosis undergoing heart transplantation [25]. Recently, a novel coagulant protein mutation was identified in a Spanish family, leading to diastolic heart failure. This mutation was associated with a higher rate of pacemaker implantation, though amyloid deposition and cytotoxicity in the heart remained relatively low [26]. Due to the diverse mutation types and high phenotypic heterogeneity of AGel amyloidosis, patients without the classic triad of symptoms may be misdiagnosed or undiagnosed. 2 cases were misdiagnosed as Sjögren’s syndrome (SS), with the initial manifestations being dry mouth, oral mucosal sensitivity, and dental caries [27, 28]. Many patients have comorbidities such as diabetes and hypertension, which may be considered as the causes of proteinuria and/or decreased renal function, potentially hindering renal biopsy in these patients. Therefore, renal AGel amyloidosis in such patients may be missed in diagnosis. Besides, a recent report described a novel gelsolin variant (c.633C > A) where proteinuria was the only presenting symptom, without the characteristic triad [29], similar to the cases presented here. Additionally, due to the rarity of AGel amyloidosis and the limited utility of routine immunohistochemistry for screening, the molecular genetic diagnosis of AGel amyloidosis currently relies primarily on mass spectrometry analysis and genetic testing. Although no disease-modifying therapy is currently available for AGel amyloidosis, symptomatic treatment generally improves the quality of life for patients. For example, ocular care such as artificial tears can effectively prevent and treat symptoms like corneal erosion and dry eyes, facial reconstructive surgery can provide short-term improvement. While AGel amyloidosis affects multiple systems, a study comparing the survival of patients with the general Finnish population found that, before the age of 75, relative survival rates were similar to those of the general population. However, after age 75, the observed survival rate was lower than the expected lifespan for both males and females. Therefore, AGel amyloidosis appears to have a minimal impact on life expectancy [11, 30]. Another study demonstrated that AGel amyloidosis increases the risk of renal complications, particularly among female patients, while overall life expectancy remains comparable to that of the general population [30]. However, in homozygous patients, disease progression is rapid, and organ transplantation can effectively extend survival time [22, 31]. A limitation of this case is the lack of genetic testing results for the patient’s family members. In conclusion, we report the first case of renal AGel amyloidosis associated with a novel GSN gene mutation (c.487G > A). It emphasizes the importance of renal biopsy, mass spectrometry analysis, and genetic testing for establishing a definitive diagnosis in patients with renal involvement as the sole clinical manifestation. Clinicians must remain vigilant to reduce missed diagnoses and misdiagnosis. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements This research was supported by The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University. Author contributions WME conducted the literature search and drafted the manuscript. CJX analyzed the patient’s clinical course and outcomes and supported the clinical data collection. CTY analyzed the pathology and mutation data. WHL conceived the study and assisted with manuscript writing and revisions. All authors have read and approved the final manuscript. Funding This work was supported by the grant of Jiaxing Key Discipline of Medicine-Nephrology (grant number 2023-ZC-011). Data availability The datasets generated and/or analysed during the current study are available at 10.6084/m9.figshare.30391732.v1. Declarations Ethics approval and consent to participate Ethical approval was obtained from the ethics committee of The First Hospital of Jiaxing. All procedures in this study involving consent to participate were performed in accordance with the ethical standards of the institutional ethics and research committee. Written informed consent was obtained from the patient for participate in this study. Consent for publication Written consent for publication of this case report was obtained from the patient. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Miner Wang and Jianxiang Chen contributed equally to this work and co-first author. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets generated and/or analysed during the current study are available at 10.6084/m9.figshare.30391732.v1.